3 Ways Property Management and Real Estate Overlap
MONONA, WI / ACCESSWIRE / June 26, 2021 / Property management and real estate are…
Month: June 2021
Flux Expanding It’s Decentralized Cloud Computing Network
Flux is set to expand with deployment of 20 additional apps, a developer grants program…
AEye Appoints LiDAR and Semiconductor Veteran Hod Finkelstein as Chief R&D Officer
New Position Expands Breadth and Depth of AEye’s Leadership as Company Continues Rapid Growth DUBLIN,…
Berrylook Monsoon-Perfect Cheap Clothes Online Are Designed For The Rainy Season Ahead
The online store recently unveiled its latest selection of monsoon-perfect clothes and accessories. Hong Kong, Hong…
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy…
Gold Springs Resource Corp. Announces Closing of Additional US$1Million Tranche of Secured Rights
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER,…
Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) — Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a privately-held…
Trillium Therapeutics Joins Russell 2000® and 3000® Indices
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (“Trillium” or the “Company”)…
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
NEW HAVEN, Conn., June 25, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company”…
Eve & Co Announces Results of Annual General Meeting
STRATHROY, Ontario, June 25, 2021 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co”…
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Report – Erytech’s Combined Shareholders’ Meeting on June 25, 2021
REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021 SS…
Cronos Group Inc. Announces Results of 2021 Annual Meeting of Shareholders
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”…
Revive Therapeutics Approved to Trade on the OTCQB Market
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:…
Cannabis Market Leader is Turning Customers Into Co-Owners
One of Europe’s largest CBD brands, Nordic Oil, has launched its first ever equity crowdfunding…
Saniona provides update on ongoing review of tesofensine in Mexico
PRESS RELEASE June 25, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on…
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive…
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic…
INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021
Houston, Texas, USA, June 25, 2021 (GLOBE NEWSWIRE) — Invectys Inc. a clinical-stage immunotherapy company…
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
Use of non-invasive measurements demonstrated that resmetirom: was safe and well-tolerated at 100 mg per…